METTL3 and breast carcinoma: m6A‐dependent upregulation of ABCD1 is associated with increased tumorigenesis and poor prognosis in ccRCC although the implication of ABCD1 in chemoresistance is not established.[42] METTL3 upregulation is associated with doxorubicin resistance in breast cancer cells due to increased expression of drug efflux pumps that decrease the therapeutic concentration of the drug inside the cells.